Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $0.59, $0.05 better than the analyst estimate of $0.54. Revenue for the quarter came in at $470 million versus the consensus estimate of $495.55 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.